close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

4.838 -0.102 (-2.06%)
Streaming Delayed Price Updated: 10:37 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Top stock movements in today's session. ↗
Via Chartmill
News headline image
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? ↗
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing. 
Via Benzinga
News headline image
ENDRA Life Sciences (NASDAQ: NDRA): The GLP-1 Healthcare Boom Offering Tremendous Opportunity Watch HIMS, ANTX, ATAI, PURR Now!
Via AB Newswire
News headline image
ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally? ↗
AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million. 
Via Stocktwits
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
AN2 Therapeutics Announces $40 Million Private Placement Financing
From AN2 Therapeutics, Inc.
Via Business Wire
Here are the top movers in Friday's session. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today